Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Achilles Therapeutics PLC Sponsored ADR (ACHL : NSDQ)
 
 • Company Description   
Achilles Therapeutics plc is a clinical-stage biopharmaceutical company. It engages in developing precision T cell therapies to treat solid tumors. Achilles Therapeutics plc is based in LONDON.

Number of Employees: 252

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.30 Daily Weekly Monthly
20 Day Moving Average: 80,547 shares
Shares Outstanding: 40.60 (millions)
Market Capitalization: $93.39 (millions)
Beta: 0.25
52 Week High: $14.39
52 Week Low: $1.84
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.35% 3.71%
12 Week -34.66% -29.10%
Year To Date -54.09% -45.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 HAMMERSMITH ROAD
-
LONDON,X0 W6 8PW
GBR
ph: 44-0-20-8154-4600
fax: -
ir@achillestx.com http://www.achillestx.com
 
 • General Corporate Information   
Officers
Iraj Ali - Chief Executive Officer and Director
Edwin Moses - Chairman of the Board of Directors Director
Robert Coutts - Chief Financial Officer
Karl Peggs - Chief Medical Officer
Sergio Quezada - Chief Scientific Officer

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00449L102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 40.60
Most Recent Split Date: (:1)
Beta: 0.25
Market Capitalization: $93.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 3.41% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 94.63%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -21.83
12/31/21 - -22.27
09/30/21 - -22.38
ROA
03/31/22 - -20.01
12/31/21 - -20.25
09/30/21 - -20.13
Current Ratio
03/31/22 - 14.51
12/31/21 - 14.90
09/30/21 - 19.41
Quick Ratio
03/31/22 - 14.51
12/31/21 - 14.90
09/30/21 - 19.41
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.56
12/31/21 - 7.13
09/30/21 - 7.51
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.03
12/31/21 - 0.03
09/30/21 - 0.03
Debt-to-Capital
03/31/22 - 2.64
12/31/21 - 2.62
09/30/21 - 2.83
 

Powered by Zacks Investment Research ©